Compare ATXG & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATXG | ACXP |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | 112 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 3.8M |
| IPO Year | N/A | 2021 |
| Metric | ATXG | ACXP |
|---|---|---|
| Price | $4.80 | $2.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $95.50 |
| AVG Volume (30 Days) | 69.2K | ★ 159.1K |
| Earning Date | 02-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.22 | $0.29 |
| 52 Week High | $7.94 | $8.34 |
| Indicator | ATXG | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 42.54 |
| Support Level | $4.79 | $1.89 |
| Resistance Level | $7.92 | $2.89 |
| Average True Range (ATR) | 1.02 | 0.22 |
| MACD | -0.34 | -0.02 |
| Stochastic Oscillator | 9.41 | 25.22 |
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.